Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C19H21NO6 |
| Molecular Weight | 359.3731 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C2=C3OCOC3=CC=C2)C(=O)OC
InChI
InChIKey=MSOAVHHAZCMHDI-UHFFFAOYSA-N
InChI=1S/C19H21NO6/c1-5-24-19(22)15-11(3)20-10(2)14(18(21)23-4)16(15)12-7-6-8-13-17(12)26-9-25-13/h6-8,16,20H,5,9H2,1-4H3
| Molecular Formula | C19H21NO6 |
| Molecular Weight | 359.3731 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Oxodipine is a dihydropyridine calcium channel blocker that has been developed by IQB as an antihypertensive agent. Experiments on dogs have shown that oxodipine exerted a relatively specific action on blood vessels without significant intrinsic negative chronotropic properties. in addition, in Europe, the drug was involved in phase III clinical trials in and in phase II for the treatment of Hypertension. Besides, oxodipine was studied for the treatment of ischaemic heart disorders. However, these studied were discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:24:59 GMT 2023
by
admin
on
Sat Dec 16 10:24:59 GMT 2023
|
| Record UNII |
2MTW8YSX8G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
56108
Created by
admin on Sat Dec 16 10:24:59 GMT 2023 , Edited by admin on Sat Dec 16 10:24:59 GMT 2023
|
PRIMARY | |||
|
2MTW8YSX8G
Created by
admin on Sat Dec 16 10:24:59 GMT 2023 , Edited by admin on Sat Dec 16 10:24:59 GMT 2023
|
PRIMARY | |||
|
119914-33-9
Created by
admin on Sat Dec 16 10:24:59 GMT 2023 , Edited by admin on Sat Dec 16 10:24:59 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER | |||
|
|
ENANTIOMER -> ENANTIOMER |
|
